Present and future of functional measurements in coronary revascularisation
- PMID: 39488223
- DOI: 10.1016/S0140-6736(24)02367-5
Present and future of functional measurements in coronary revascularisation
Conflict of interest statement
MJS declares a ZonMW Efficacy Studies grant (2021) for the iCORONARY trial (Improving the Cost-effectiveness of Coronary Artery Disease Diagnosis) and a ZonMW Promising Care grant (2022) for the TRACE-NL trial (Evaluation of the safety, efficacy and cost-effectiveness of transcatheter tricuspid valve repair in patients with severe tricuspid regurgitation in the Netherlands); and has received consultancy fees from Abbott Vascular, Bioventrix, Boston Scientific, Cardiac Dimensions, Edwards Lifesciences, GE Healthcare, Medtronic, Philips Healthcare, P&F, and Siemens Healthcare. LMB declares no competing interests.
Comment on
-
Quantitative flow ratio versus fractional flow reserve for coronary revascularisation guidance (FAVOR III Europe): a multicentre, randomised, non-inferiority trial.Lancet. 2024 Nov 9;404(10465):1835-1846. doi: 10.1016/S0140-6736(24)02175-5. Epub 2024 Oct 30. Lancet. 2024. PMID: 39488224 Clinical Trial.
Publication types
LinkOut - more resources
Full Text Sources
